advertisement
Frontiers in pharmacology 45
Showing records 1 to 25 | Display all abstracts in Frontiers in pharmacology128095 Intravitreal drug injection for glaucoma: mechanisms, clinical efficacy, and future horizons
Lin B
Frontiers in pharmacology 2025; 16: 1660401
128148 Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact
Xie Z
Frontiers in pharmacology 2025; 16: 1618079
128813 A comprehensive and systematic review on resveratrol supplementation as a promising candidate for the retinal disease: a focus on mechanisms of action from preclinical studies
Lv XM
Frontiers in pharmacology 2025; 16: 1615910
128064 Efficacy and safety of stem cells in the treatment of glaucoma: systematic review and meta-analysis based on animal experiments
Wu D
Frontiers in pharmacology 2025; 16: 1587440
128774 Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
Lin Z
Frontiers in pharmacology 2025; 16: 1623921
127992 Shikonin as a therapeutic agent in renal cell carcinoma: insights from TEK-related causal association with glaucoma
Jia R
Frontiers in pharmacology 2025; 16: 1580704
128586 Broad-spectrum therapeutic potential of 4-phenylbutyrate in neurological and systemic diseases of viral and non-viral origin
Bobat F
Frontiers in pharmacology 2025; 16: 1621590
128826 Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS)
Li X
Frontiers in pharmacology 2025; 16: 1498814
128774 Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
Xue J
Frontiers in pharmacology 2025; 16: 1623921
127992 Shikonin as a therapeutic agent in renal cell carcinoma: insights from TEK-related causal association with glaucoma
Liang Y
Frontiers in pharmacology 2025; 16: 1580704
128586 Broad-spectrum therapeutic potential of 4-phenylbutyrate in neurological and systemic diseases of viral and non-viral origin
Wu D
Frontiers in pharmacology 2025; 16: 1621590
128826 Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS)
Zhang SQ
Frontiers in pharmacology 2025; 16: 1498814
128095 Intravitreal drug injection for glaucoma: mechanisms, clinical efficacy, and future horizons
Shi P
Frontiers in pharmacology 2025; 16: 1660401
128148 Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact
Yang Z
Frontiers in pharmacology 2025; 16: 1618079
128813 A comprehensive and systematic review on resveratrol supplementation as a promising candidate for the retinal disease: a focus on mechanisms of action from preclinical studies
Li N
Frontiers in pharmacology 2025; 16: 1615910
128064 Efficacy and safety of stem cells in the treatment of glaucoma: systematic review and meta-analysis based on animal experiments
Liu Y
Frontiers in pharmacology 2025; 16: 1587440
128774 Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
Yang M
Frontiers in pharmacology 2025; 16: 1623921
127992 Shikonin as a therapeutic agent in renal cell carcinoma: insights from TEK-related causal association with glaucoma
Zou B
Frontiers in pharmacology 2025; 16: 1580704
128586 Broad-spectrum therapeutic potential of 4-phenylbutyrate in neurological and systemic diseases of viral and non-viral origin
Tu E
Frontiers in pharmacology 2025; 16: 1621590
128826 Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS)
Wang KR
Frontiers in pharmacology 2025; 16: 1498814
128095 Intravitreal drug injection for glaucoma: mechanisms, clinical efficacy, and future horizons
Li DK
Frontiers in pharmacology 2025; 16: 1660401
128148 Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact
Tian D
Frontiers in pharmacology 2025; 16: 1618079
128813 A comprehensive and systematic review on resveratrol supplementation as a promising candidate for the retinal disease: a focus on mechanisms of action from preclinical studies
Chen LW
Frontiers in pharmacology 2025; 16: 1615910
128064 Efficacy and safety of stem cells in the treatment of glaucoma: systematic review and meta-analysis based on animal experiments
Zhang X
Frontiers in pharmacology 2025; 16: 1587440
128826 Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS)
Wu SN
Frontiers in pharmacology 2025; 16: 1498814
